Base to Base biotech podcast 29: Blood pressure and radiopharmaceuticals

This week, we have two interviews again. We talk about treating high blood pressure with CEO of George Medicines, Mark Mallon, and have a conversation with Jack Hoppin, CEO of Ratio Therapeutics, and John Babich, CSO, about the field of radiotherapeutics.Blood pressureNearly half of US adults have high blood pressure and despite all the treatments already available, three in four remain uncontrolled. This is often because the traditional stepwise treatment approach stalls before reaching target blood pressure.George Medicines believes its solution could help millions of patients achieve better outcomes, faster.The company has developed the first and only triple combination pill for the initial treatment of high blood pressure. It’s available in unique low dose options, offering the power of combination therapy, with good tolerability, in a single pill — a paradigm shift in hypertension care. This drug is the first to be approved for use right at the start of treatment.The company is a spinout from the George Institute for Global Health in Australia.RadiopharmaceuticalsRadiopharmaceuticals sit at the intersection of nuclear medicine and precision therapy, offering a way to deliver radiation directly to tumours while sparing healthy tissue.The next wave of oncology innovation is changing how we think about cancer therapy, but it comes with unique challenges—from isotope supply and manufacturing logistics to regulatory navigation and the race to harness rare isotopes like actinium-225.Jack Hoppin, CEO of Ratio Therapeutics, and John Babich, CSO, are leaders in this space, and they are our guests on the podcast today. Their company is developing next-generation radiopharmaceuticals using proprietary platforms (Trillium and Macropa) designed to enhance tumour targeting and drug design.To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email [email protected]